GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » Retained Earnings

Calithera Biosciences (STU:2CB0) Retained Earnings : €-483.91 Mil (As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Calithera Biosciences's retained earnings for the quarter that ended in Dec. 2022 was €-483.91 Mil.

Calithera Biosciences's quarterly retained earnings declined from Jun. 2022 (€-469.10 Mil) to Sep. 2022 (€-510.74 Mil) but then increased from Sep. 2022 (€-510.74 Mil) to Dec. 2022 (€-483.91 Mil).

Calithera Biosciences's annual retained earnings declined from Dec. 2020 (€-309.27 Mil) to Dec. 2021 (€-434.82 Mil) and declined from Dec. 2021 (€-434.82 Mil) to Dec. 2022 (€-483.91 Mil).


Calithera Biosciences Retained Earnings Historical Data

The historical data trend for Calithera Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Retained Earnings Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -172.43 -257.49 -309.27 -434.82 -483.91

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -434.82 -458.69 -469.10 -510.74 -483.91

Calithera Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Calithera Biosciences  (STU:2CB0) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Calithera Biosciences (STU:2CB0) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines